Gillian McGovern, Associate Editor

The newly-approved intrauterine device (IUD) prevents pregnancy in people of reproductive potential for up to 3 years.

Although tenofovir amibufenamide and tenofovir disoproxil fumarate (TDF) had similar effects, the former resulted in better renal safety and did not impact lipid levels.

The authors note that this lack of inclusion can leave important safety and efficacy questions unanswered.

The designation is supported by pooled data from 4 clinical trials.

Levonorgestrel-releasing intrauterine devices were not found to increase women’s risks of these conditions.

The FDA-approved treatment did not cause as many adverse events as immunotherapy when treating patients with multi-food allergy.

The long-term durability of response will be evaluated in the B-Sure trial (NCT04954859), which will enroll patients with hepatitis B virus (HBV) from B-Together (NCT04676724).

Currently, the agent is undergoing evaluation in a phase 2 clinical trial to determine its safety and efficacy.

This marks the first FDA-approved treatment for this rare lipid storage disease.

In children aged 1 to 3 years, the VP250 peanut patch was superior to placebo in the desensitization to peanuts and increasing the peanut dose that triggers allergic symptoms.

These findings may lead to new therapies to help reduce the risk of heart disease in women who are at risk.

Although larsucosterol did not show statistical significance, it showed clinically meaningful trends in 90-day mortality in patients with severe alcohol-associated hepatitis.

The authors are optimistic that these findings may help develop defenses to prevent food allergies in at-risk infants.

Future research can explore the underlying cause of recurrent pericarditis with systemic Sjögren syndrome and the combination of rilonacept with immunosuppressive therapies.

The authors suggest future research should consider inflammation and the gut as potential therapeutic targets improve depression in patients with chronic kidney disease (CKD).

The indication is for symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.

Pharmacists can help patients and their caregivers manage seizures, assess seizure control, and recommend appropriate treatments such as phenobarbital or rescue medications.

Pharmacists can help educate patients, identify adverse events, and help patients communicate with other health care professionals or drug companies.

After gradually consuming increased doses of peanut butter, children who could initially tolerate about half a peanut could consume 3 tablespoons without an allergic reaction.

Through frequent interactions, pharmacists can discuss patients' treatment satisfaction, adherence issues, or potential adverse events.

This surgery can be significant in reducing the long-term risk of adverse outcomes and decompensation in cirrhosis related to metabolic dysfunction-associated steatohepatitis (MASH).

Currently, the Cadherin-6 targeting antibody-drug conjugate is undergoing evaluation in a phase 1a/1b clinical trial.

The approval follows the ECHELON-3 study, which enrolled adults with relapsed or refractory large B-cell lymphoma.

Reductions in cerebellar volume were associated with cognitive deficits and lower kidney function in those with CKD.

Supplements, such as Prevagen, as well as lifestyle and diet modifications can provide additional support to patients with Alzheimer disease.

If approved, brensocatib will be the first and only approved treatment for bronchiectasis and the first within a new class of medicines, called dipeptidyl peptidase 1 inhibitors.

The decision to end HYPERION (NCT04811092) comes after positive results from an interim analysis of the ZENITH trial (NCT04896008).

The authors are optimistic that this method can be replicated to identify other allergens that manifest into eosinophilic esophagitis (EoE).

In the phase 3 CONNEX clinical trial program, iclepertin did not meet its primary and secondary end points.

The indication is for patients with endometrial cancer who may benefit from treatment with ACR-368 (Acrivon Therapeutics).